ft 12 jul 94 eli lilli test new formula plan purchas come us drug industri reshap eli lilli plan purchas pc pharmaci benefit manag compani look set complet reshap big part us drug distribut busi finalis bring three number benefit manag sold less year total consider around dollar 13bn two other caremark valu health form close tie drug manufactur recent month though stop short outright sale low growth us drug market manufactur hope control distribut help gain market share pharmaci benefit manag fill prescript big buyer healthcar formulari list recommend drug exercis consider influenc drug patient buy accord figur provid distributor influenc drug buy habit grow fast five mention claim 75m peopl formulari account nearli one three american pc biggest measur claim 30m peopl custom growth come convert exist custom formulari approach though also big new contract pc wide believ less interventionist sale drug rival like medco merck subsidiari take activ approach doctor prescrib habit telephon physician encourag switch medco recommend drug whenev patient submit prescript drug formulari futur pc like emul medco close informat capac interven said mr jame corneliu eli lilli chief financi offic eli lilli probabl need acquir pharmaci benefit manag pharmaceut compani group sale growth first quarter year slow 3 per cent far cri headi doubl digit growth earli 1990 certainli wors competitor compani especi hit increasingli acut competit environ us eli lilli import market antibiot anti depress ulcer therapi undermin price competit bulk purchas medicin effect made product commod take prozac eli lilli top sell anti depress first central nervou system medicin achiev sale dollar 1bn although prozac first market slew competitor pfizer zoloft smithklin beecham paxil undermin drug growth eli lilli also perform poorli increasingli difficult antibiot market ceclor group top sell antibiot lost us patent protect 1992 post sale 9 5 per cent dollar 515m successor drug lorabid prove disappoint final axid compani fourth import medicin continu compet increasingli turbul anti ulcer market smithklin beecham competitor product tagamet lost us patent protect may earli data suggest axid share new prescript fall theori put forward yesterday mr randal tobia eli lilli chairman chief execut pc health system offset increasingli difficult environ remain seen though whether pharmaci benefit manag sustain difficult balanc act push one manufactur product time convinc custom provid best drug best price patient pc yesterday said acquisit eli lilli would make differ select drug formulari instanc though stanc seem disingenu given eli lilli willing pay dollar 4bn cash distributor judg wall street initi reaction yesterday eli lilli pay much secur line distribut slide share price prospect rate downgrad reflect gener belief deal would weaken compani financi fail produc suffici sale growth justifi price tag cash come futur sale busi mr corneliu said compani plan rais dollar 500m dollar 600m tax sale 40 per cent stake elanco agricultur product compani jointli own dow chemic approach made dow first right buy stake dollar 1bn come previous announc flotat sale compani diagnost busi complet end year mr corneliu said around dollar 1bn cash slightli dollar 1bn debt moment lilli balanc sheet bear strain dollar 4bn new debt pay dollar 1 5bn proce sale would left debt equiti ratio around 40 per cent mr corneliu said take time financi ramif deal turn posit though even base lilli assumpt accord compani 1997 higher sale result pc acquisit begin outweigh extra debt servic cost